Company intelligence / Profile preview

Vet Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Developed canine monoclonal antibodies for B-cell and T-cell lymphoma; B-cell product granted conditional USDA license and commercialized in certain territories under distribution agreement; T-cell product submitted to USDA; showed improved remission times in studies when combined with chemotherapy.

Therapeutic areas: OncologyDermatology
Modalities: Monoclonal antibody
Industry: Veterinary

Partnerships

Large animal health company (distribution for B-cell lymphoma product)

Beyond the preview

Go deeper on Vet Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vet Therapeutics.

Explore the full profile